Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

AMN Healthcare Services

Royal Philips

R1 RCM Inc

The booming digital health space has been witnessing significant M&A activities amid the pandemic.

Digital Health M&As Gain Precedence in the New Normal

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial and operational results for the full-year ended January 2, 2021 and provided estimates for its full-year 2021 financial guidance. Preliminary Full-Year 2020 Results: Masimo expects that its product revenue for the full-year 2020 will range from $1.139 billion to $1.144 billion, which reflects reported growth of 21.6% to 22.2% and constant currency growth of 21.6% to 22.1%, respectivel

Masimo Announces Select Preliminary Full-Year 2020 Financial Results and 2021 Guidance

Masimo (MASI) is lending support to Renown Health through Masimo SafetyNet in order to manage the COVID-19 surge.

Masimo's (MASI) Telehealth Solution Helps in COVID-19 Crisis

IRVINE, Calif.--(BUSINESS WIRE)--Masimo is helping Renown Health address the COVID-19 surge, in part through use of Masimo SafetyNet™, a remote patient management solution.

Masimo Helps Clinicians at Renown Health Manage the COVID-19 Surge

Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.

Masimo (MASI) Releases Favorable Findings on Pulse Oximetry

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study used Masimo ORi™, Oxygen Reserve Index, to help limit the extent of postoperative hyperoxia.

Researchers Use Masimo ORi™, Oxygen Reserve Index, to Help Suppress Postoperative Hyperoxia in Patients Undergoing Breast Surgery

NEUCHATEL, Switzerland--(BUSINESS WIRE)--In a study of pediatric patients, Masimo SpHb® was associated with improved outcomes, including reduced postoperative transfusion and ICU stays.

New Study Associates Masimo SpHb®, Noninvasive and Continuous Hemoglobin Monitoring, as Part of Pediatric Patient Blood Management, with Reduced ICU Stays and Postoperative Transfusion

IRVINE, Calif.--(BUSINESS WIRE)--Masimo was featured at CLSA's Pantheon 2020 conference for its efforts to help clinicians and hospitals combat COVID-19.

Masimo's COVID-19 Response Efforts Highlighted at California Life Sciences Association's Pantheon 2020

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on Wednesday, December 2, 2020 at 3:30 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a

Masimo to Present in Piper Sandler Virtual Healthcare Conference

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study of mechanically ventilated patients compared Masimo PVi® to another noninvasive fluid responsiveness indicator and found PVi advantageous.

Study Comparing Two Noninvasive Indicators of Fluid Responsiveness on Mechanically Ventilated Patients Finds Masimo PVi® Effective and Advantageous

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide ar

Masimo to Present in Stifel Virtual Healthcare Conference

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A cancer study using a PBM program with Masimo SpHb® found decreased RBC units transfused per patient and increased transfusion appropriateness.

Study Investigates Effects of Patient Blood Management Program with Masimo SpHb®, Noninvasive, Continuous Hemoglobin Monitoring, on Postoperative Cancer Patients

IRVINE, Calif.--(BUSINESS WIRE)--Joe Kiani, Founder & CEO of Masimo & co-inventor of measure-through-motion pulse oximetry, was honored by SIBEN for improvements to neonatal health.

Masimo Founder and CEO and Co-Inventor of Measure-Through-Motion Pulse Oximetry, Joe Kiani, Awarded by the Ibero-American Society of Neonatology for Improvements to Neonatal Health in Latin America

Edwards Lifesciences

Franco-Nevada C

There are many useful nooks and crannies on the GuruFocus website, including screeners that help us find stocks outside the mainstream.

3 Strong, Margin-Expanding Stocks

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo Radius VSM™, a versatile, expandable, wearable, tetherless vital signs monitor, has received CE marking and limited market release in Europe.

Masimo Announces Limited Market Release of Radius VSM™

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q3

Masimo Corporation (MASI) CEO Joe Kiani on Q3 2020 Results - Earnings Call Transcript

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the third quarter ended September 26, 2020. Third Quarter 2020 Results: Total revenue, including royalty and other revenue, increased 21.4% to $278.1 million, compared to $229.0 million in the third quarter of 2019. Product revenue increased 21.5% to $278.1 million, or 21.1% on a constant currency basis, compared to $228.9 million in the third quarter of 2019. Excluding handheld and fingertip pulse

Masimo Reports Third Quarter 2020 Financial Results

Masimo is trading near a potential buy area ahead of its next quarterly earnings report, expected on or around Oct. 27. The post Masimo Near Later-Stage Buy Point Ahead Of Earnings Report appeared first on Investor's Business Daily.

Masimo Near Later-Stage Buy Point Ahead Of Earnings Report

Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo (MASI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release third quarter 2020 financial results for the period ended September 26, 2020, after the market closes on Tuesday, October 27, 2020. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, pleas

Masimo to Report Third Quarter 2020 Financial Results after Market Close on Tuesday, October 27

Masimo is near a buy zone with earnings due on or around Oct. 27. The post Highly Rated Masimo Forms Later-Stage Base With Earnings Due appeared first on Investor's Business Daily.

Highly Rated Masimo Forms Later-Stage Base With Earnings Due

NEUCHATEL, Switzerland--(BUSINESS WIRE)--In an ASA abstract, researchers investigated whether Masimo ORi™ could predict the need for postoperative oxygen therapy in children with sleep apnea.

Researchers Use Masimo ORi™, Oxygen Reserve Index, to Predict the Need for Postoperative Oxygen Therapy in Pediatric Patients with Obstructive Sleep Apnea

Masimo's (MASI) wearable wireless continuous thermometer offers consumers hassle-free continuous body temperature measurements, thereby eliminating the need for manual measurements.

Masimo Unveils New Wearable Wireless Continuous Thermometer

Masimo, a maker medical devices that include a Covid-19 monitor, finally gave its first 2020 guidance and also posted preliminary third-quarter sales that beat expectation; MASI stock rose. The post Masimo Gives Its First 2020 Guidance After Covid-19 'Uncertainties'; MASI Stock Rises appeared first on Investor's Business Daily.

News for Masimo Stock (MASI)